Durect Quick Ratio (DRRX) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Durect Corp  (NASDAQ: DRRX)

Durect's Quick Ratio

DRRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2025, Quick Ratio fell to 0.82 below Durect Corp average.

Within Major Pharmaceutical Preparations industry 324 other companies have achieved higher Quick Ratio than Durect in second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from 1504 to 1509.

Explain Quick Ratio?
How much Cash & cash equivalents DRRX´s has?
What are DRRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DRRX Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change -64 % -68.98 % -75.16 % -45.02 % -47.07 %
Y / Y Cash & cash equivalent Change -58.44 % -61.47 % -60.23 % -73.38 % -55.16 %
Quick Ratio MRQ 0.82 1.08 1.53 0.51 0.71
DRRX's Total Ranking # 1509 # 1504 # 1286 # 1871 # 1866
Seq. Current Liabilities Change 2.87 % -0.48 % -61.84 % -7.85 % -11.36 %
Seq. Cash & cash equivalent Change -21.28 % -30.02 % 13.75 % -33.68 % -27.02 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 325
Healthcare Sector # 585
Overall Market # 1509


Quick Ratio Statistics
High Average Low
10.76 3.55 0.51
(Jun 30 2021)   (Sep 30 2024)




Financial Statements
Durect's Current Liabilities $ 8 Millions Visit DRRX's Balance sheet
Durect's Cash & cash equivalent $ 7 Millions Visit DRRX's Balance sheet
Source of DRRX's Sales Visit DRRX's Sales by Geography


Cumulative Durect's Quick Ratio

DRRX's Quick Ratio for the trailling 12 Months

DRRX Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -62.01 % -57.06 % -50.71 % -35.77 % -11.3 %
Y / Y Cash & cash equivalent TTM Growth -65.07 % -63.13 % -59.94 % -52.3 % -39.45 %
Quick Ratio TTM 0.85 0.8 0.79 0.79 0.92
Total Ranking TTM # 2833 # 2933 # 2825 # 3267 # 2841
Seq. Current Liabilities TTM Growth -24.4 % -22.88 % -23.83 % -14.45 % -14.56 %
Seq. Cash & cash equivalent TTM Growth -19.84 % -22.24 % -23.17 % -27.05 % -15.4 %

Quick ratio ranking by company, industry and sector >> Back to DRRX Financial Strength Comparisons >> Go to Compare DRRX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Durect's average Cash & cash equivalent, this led to increase in in Durect's Quick Ratio to 0.85, Quick Ratio remained below DRRX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 392 other companies have achieved higher Quick Ratio than Durect. While Quick Ratio overall ranking has improved so far to 2833, from total ranking during the twelve months ending first quarter 2025 at 2933.

Explain Quick Ratio?
How much Cash & cash equivalents DRRX´s has?
What are DRRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 393
Healthcare Sector # 810
Within the Market # 2833


trailing twelve months Quick Ratio Statistics
High Average Low
8.5 3.24 0.79
(Dec 31 2021)   (Dec 31 2024)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Rhythm Pharmaceuticals Inc   2.26 $ 291.030  Millions$ 128.945  Millions
Veru Inc   2.25 $ 15.010  Millions$ 6.682  Millions
Ultragenyx Pharmaceutical Inc   2.24 $ 487.585  Millions$ 217.615  Millions
Elicio Therapeutics Inc   2.23 $ 22.088  Millions$ 9.923  Millions
Gri Bio Inc   2.22 $ 5.122  Millions$ 2.309  Millions
Oculis Holding Ag  2.21 $ 81.329  Millions$ 36.747  Millions
Alnylam Pharmaceuticals Inc   2.20 $ 2,857.585  Millions$ 1,300.847  Millions
Telomir Pharmaceuticals Inc   2.17 $ 0.754  Millions$ 0.348  Millions
Zai Lab Limited  2.15 $ 730.971  Millions$ 339.795  Millions
Emergent Biosolutions Inc   2.10 $ 267.300  Millions$ 127.100  Millions
Biomarin Pharmaceutical Inc  2.09 $ 1,432.125  Millions$ 684.247  Millions
Enveric Biosciences Inc   2.09 $ 2.850  Millions$ 1.364  Millions
Spero Therapeutics Inc   2.09 $ 31.194  Millions$ 14.945  Millions
Nls Pharmaceutics Ltd  2.07 $ 3.072  Millions$ 1.481  Millions
Kala Bio inc   2.05 $ 31.942  Millions$ 15.610  Millions
Mallinckrodt Plc  2.05 $ 390.300  Millions$ 190.800  Millions
Ainos Inc   2.03 $ 1.223  Millions$ 0.603  Millions
Immunic Inc   2.03 $ 55.310  Millions$ 27.313  Millions
Scpharmaceuticals Inc   2.02 $ 40.809  Millions$ 20.166  Millions
Maia Biotechnology Inc   2.01 $ 10.145  Millions$ 5.044  Millions
Alkermes Plc   2.01 $ 1,015.739  Millions$ 505.962  Millions
Prf Technologies Ltd   2.00 $ 4.510  Millions$ 2.258  Millions
Metavia Inc   1.99 $ 17.589  Millions$ 8.820  Millions
Allarity Therapeutics Inc   1.97 $ 17.801  Millions$ 9.038  Millions
Aptevo Therapeutics Inc   1.92 $ 9.410  Millions$ 4.891  Millions
Apellis Pharmaceuticals Inc   1.91 $ 370.036  Millions$ 193.240  Millions
Cellectar Biosciences Inc   1.91 $ 11.041  Millions$ 5.775  Millions
Greenwich Lifesciences Inc   1.85 $ 3.125  Millions$ 1.686  Millions
Arcutis Biotherapeutics Inc   1.84 $ 190.823  Millions$ 103.936  Millions
Urogen Pharma Ltd   1.81 $ 92.921  Millions$ 51.348  Millions

Date modified: 2026-08-29T17:24:28+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.